Mibg (123i) Curium Netherlands (Iodine (123i) Iobenguane)

Iobenguane (I-123) is used in nuclear‑medicine procedures that assess sympathetic innervation and catecholamine‑producing tumors.

• Myocardial innervation imaging: visualizes cardiac sympathetic nerve distribution to evaluate autonomic function.
• Pheochromocytoma detection: highlights catecholamine‑secreting adrenal tumors for accurate localization.
• Neuroblastoma imaging: identifies sympathetic‑origin pediatric tumors and assesses disease extent.

• Iobenguane (I‑123) mimics norepinephrine and is taken up by adrenergic nerve terminals via the norepinephrine transporter. Once internalized, the radio‑iodine emits gamma photons that are captured by a gamma camera, allowing three‑dimensional visualization of sympathetic innervation and catecholamine‑producing lesions during nuclear imaging.

Adverse reactions are generally mild but can occur after intravenous administration.

Common Side Effects

• Injection site pain or erythema
• Nausea or mild vomiting
• Transient headache
• Flushing or warmth sensation
• Mild hypotension
• Dizziness or light‑headedness

Serious or Rare Side Effects

• Anaphylactic or severe allergic reaction
• Significant hypotension requiring intervention
• Radiation‑induced thyroid dysfunction
• Bone‑marrow suppression with prolonged exposure
• Severe arrhythmias in patients with underlying cardiac disease
• Acute renal impairment in susceptible individuals

Prior to use, clinicians should evaluate patient‑specific factors that may affect safety or image quality.

• Pregnancy: avoid unless the diagnostic benefit outweighs fetal radiation risk.
• Breastfeeding: discontinue nursing for an appropriate interval after administration.
• Thyroid blocking: consider potassium iodide pretreatment to reduce thyroid uptake of free iodine.
• Renal function: assess because the tracer is excreted renally and impaired function may increase radiation exposure.
• Concomitant norepinephrine‑modulating drugs: may alter tracer distribution and affect image interpretation.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iobenguane (I‑123) may have interactions that influence tracer uptake or patient safety.

Major Interactions (Avoid)

• Thyroid blocking agents (e.g., potassium iodide) that compete for iodine uptake and reduce image quality.
• Strong norepinephrine transporter inhibitors (e.g., reserpine, certain antidepressants) that markedly diminish tracer accumulation.
• High‑dose radiopharmaceuticals administered within 24 hours, which can increase cumulative radiation dose.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt heart‑rate response during cardiac imaging.
• Calcium‑channel blockers: can modestly affect myocardial perfusion patterns.
• Other diagnostic radiotracers given in close succession: may cause cross‑interference on imaging results.